Efficacy of oral corticosteroids for acute preschool wheeze: a systematic review and individual participant data meta-analysis of randomised clinical trials
- PMID: 38527486
- DOI: 10.1016/S2213-2600(24)00041-9
Efficacy of oral corticosteroids for acute preschool wheeze: a systematic review and individual participant data meta-analysis of randomised clinical trials
Abstract
Background: Oral corticosteroids are commonly used for acute preschool wheeze, although there is conflicting evidence of their benefit. We assessed the clinical efficacy of oral corticosteroids by means of a systematic review and individual participant data (IPD) meta-analysis.
Methods: In this systematic review with IPD meta-analysis, we systematically searched eight databases (PubMed, Ovid Embase, CINAHLplus, CENTRAL, ClinicalTrials.gov, EudraCT, EU Clinical Trials Register, WHO Clinical Trials Registry) for randomised clinical trials published from Jan 1, 1994, to June 30, 2020, comparing oral corticosteroids with placebo in children aged 12 to 71 months with acute preschool wheeze in any setting based on the Population, Intervention, Comparison, Outcomes framework. We contacted principal investigators of eligible studies to obtain deidentified individual patient data. The primary outcome was change in wheezing severity score (WSS). A key secondary outcome length of hospital stay. We also calculated a pooled estimate of six commonly reported adverse events in the follow-up period of IPD datasets. One-stage and two-stage meta-analyses employing a random-effects model were used. This study is registered with PROSPERO, CRD42020193958.
Findings: We identified 16 102 studies published between Jan 1, 1994, and June 30, 2020, from which there were 12 eligible trials after deduplication and screening. We obtained individual data from seven trials comprising 2172 children, with 1728 children in the eligible IPD age range; 853 (49·4%) received oral corticosteroids (544 [63·8%] male and 309 [36·2%] female) and 875 (50·6%) received placebo (583 [66·6%] male and 292 [33·4%] female). Compared with placebo, a greater change in WSS at 4 h was seen in the oral corticosteroids group (mean difference -0·31 [95% CI -0·38 to -0·24]; p=0·011) but not 12 h (-0·02 [-0·17 to 0·14]; p=0·68), with low heterogeneity between studies (I2=0%; τ2<0·001). Length of hospital stay was significantly reduced in the oral corticosteroids group (-3·18 h [-4·43 to -1·93]; p=0·0021; I2=0%; τ2<0·001). Subgroup analyses showed that this reduction was greatest in those with a history of wheezing or asthma (-4·54 h [-5·57 to -3·52]; pinteraction=0·0007). Adverse events were infrequently reported (four of seven datasets), but oral corticosteroids were associated with an increased risk of vomiting (odds ratio 2·27 [95% CI 0·87 to 5·88]; τ2<0·001). Most datasets (six of seven) had a low risk of bias.
Interpretation: Oral corticosteroids reduce WSS at 4 h and length of hospital stay in children with acute preschool wheeze. In those with a history of previous wheeze or asthma, oral corticosteroids provide a potentially clinically relevant effect on length of hospital stay.
Funding: Asthma UK Centre for Applied Research.
Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests BL received a PhD studentship from AUKCAR programme (AUK-AC-2018–01) funded by Asthma + Lung UK. SC received institutional grants for BL's PhD studentship via AUKCAR. PC reports grants from Juhani Aho Foundation for Medical Research, Allergy Research Foundation, Tampere Tuberculosis Foundation, the Research Foundation of the Pulmonary Diseases, The Finnish Medical Foundation, and The Jalmari and Rauha Ahokas Foundation; consulting fees from ALK, Sanofi, and Thermo Fisher; payments for expert testimony from Sanofi; support for attending meetings or travel from ALK and Orion Pharma; and participation on a Data Safety Monitoring Board or Advisory Board for ALK and Sanofi. TWG reports grants from GSK, Sanofi, Regeneron, Amgen, AstraZeneca, and OM Pharma; royalties and licenses from UpToDate; consulting fees from Sanofi, Regeneron, AstraZeneca, Genentech, Polarean, and OM Pharma; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Sanofi, Regeneron, AiCME, PlatformQ Health, and Advent; support for attending meetings or travel from AiCME, PlatformQ Health, and Advent; and participation on a Data Safety Monitoring Board or Advisory Board for Best Pharmaceuticals for Children Act. JG reports grants from OM Pharma and Mariomed Biotech; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from OM Pharma, GSK, AstraZeneca, and Sanofi; payment for expert testimony from a London coroner regarding the case of a child who died of asthma; and receipt of equipment, materials, drugs, medical writing, gifts, or other services from Omron. All other authors declare no competing interests.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
